4D Molecular Therapeutics taps Kristian Humer as CFO
Source: SeekingAlpha
2025-11-17 06:17:17 ET
More on 4D Molecular Therapeutics
- 4D Molecular Therapeutics: This Gene Therapy Company May Soon Surprise Investors
- 4D Molecular Therapeutics, Inc. (FDMT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
- 4D Molecular Therapeutics stock rises after pricing $100M offering
- Seeking Alpha’s Quant Rating on 4D Molecular Therapeutics
- Historical earnings data for 4D Molecular Therapeutics
Read the full article on Seeking Alpha
For further details see:
4D Molecular Therapeutics taps Kristian Humer as CFO
4D Molecular Therapeutics Inc.
NASDAQ: FDMT
FDMT Trading
-1.66% G/L:
$8.27 Last:
104,610 Volume:
$8.35 Open:
FDMT Latest News
FDMT Stock Data
$519,643,507
47,993,463
N/A
51
N/A
Biotechnology & Life Sciences
Healthcare
US
Emeryville
